Know What's Happening in BioTech
Know What's Happening in BioTech
BioTech Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
Alumis announced that its TYK2 inhibitor envudeucitinib met primary endpoints in two Phase 3 psoriasis trials, delivering 74% of patients achieving PASI‑75 after four months. The data suggest efficacy comparable to leading oral candidates and injectable biologics, prompting the stock to more than double to about $17 per share. The company plans to file for U.S. approval later in 2026, while also testing the drug in other immune disorders such as Crohn’s disease and lupus.
Researchers have unveiled the “Stomata in‑Sight” platform, a real‑time imaging system that visualizes stomatal opening and closing on living leaves. By combining high‑speed microscopy with machine‑learning algorithms, the tool records pore dynamics at sub‑second intervals. Early trials demonstrate precise measurements...
Chromatin Bioscience, Mediphage Bioceuticals, and Entos Pharmaceuticals announced a joint genetic‑medicine project funded by UKRI Innovate UK and Canada’s NRC IRAP. The partnership merges Chromatin Bioscience’s chromatinLENS synthetic‑promoter platform, Mediphage’s msDNA linear DNA technology, and Entos’s Fusogenix PLV fusion‑based delivery system....
Arrowhead Pharma reported that its RNAi drug ARO‑INHBE, combined with Eli Lilly’s tirzepatide, produced roughly double the weight loss seen with tirzepatide alone in a small Phase I/IIa study. In the interim analysis, patients receiving the combo lost 9.4% of body weight...
Eli Lilly has struck a new multi‑year collaboration with Nimbus Therapeutics, paying $55 million upfront for a preclinical oral obesity drug program that could generate up to $1.3 billion in milestones. The partnership leverages Nimbus’s AI‑driven, structure‑based design to discover small‑molecule treatments for...
Scientists at University College London have demonstrated that spent yeast from beer brewing can be converted into bacterial cellulose scaffolds suitable for cultivated meat production. The yeast‑derived cellulose matches or exceeds the texture of conventional scaffolds while being edible and...
2025 drug discovery emphasized rigorous target selection, with genetics‑driven programs outpacing unvalidated approaches. Immunology saw a breakthrough as small‑molecule degraders and inhibitors of transcription factors IRF5 and STAT6 demonstrated oral activity, challenging the dominance of biologics. Emerging modalities such as...
Researchers at the University of Illinois’s Center for Advanced Bioenergy and Bioproducts Innovation demonstrated a sustainable route to produce triacetic acid lactone (TAL) from sugarcane using fermentation followed by crystallization. By coupling experimental solubility data with the BioSTEAM simulation platform,...
Cornell researchers have shown that ultrasmall core‑shell silica nanoparticles, dubbed "prime dots," can reprogram the tumor microenvironment of melanoma, activating innate immunity and converting immunologically "cold" tumors into "hot" ones. The study published in Nature Nanotechnology documents multiple mechanisms—including pattern‑recognition...
Recent 3‑D reconstructions reveal that the mitochondrial contact site and cristae organizing system (MICOS) becomes progressively disordered in aging neurons, especially those exposed to Alzheimer’s disease (AD) pathology. The study documents age‑dependent cristae fragmentation, reduced inter‑mitochondrial connectivity, and altered mitochondrial...
A recent study using a 12‑week supervised exercise program showed a modest reversal of proteomic aging, shrinking the predicted biological age by roughly ten months in 26 male participants. The research linked higher ProtAgeGap scores to lower physical activity and...
Columbia engineers have created BEAT, an inhalable nanotherapy that uses engineered exosomes to co‑deliver PD‑1/PD‑L1 and Wnt/β‑catenin inhibitors directly to lung metastases of melanoma. In mouse models resistant to checkpoint inhibitors, inhaled BEAT achieved superior lung retention, dramatically suppressed tumor...
Swiss biotech Argenx announced that Dr. Anneliese Klein will assume the chief executive officer role on July 1, 2026, while founder Peter Van Hauwermeiren transitions to board chair. Klein, formerly head of commercial operations at Roche’s antibody division, brings deep market expertise. Van’s move...
The BioCentury podcast kicked off 2026 by evaluating biotech trends across the United States, Europe and Asia. Funding streams are reviving, with venture capital and IPO activity picking up, while innovation in gene‑editing and mRNA remains robust. At the same...
Australian biotech ENA Respiratory has unveiled a pan‑viral nasal spray that primes the host’s innate immune system to block a broad range of upper‑respiratory viruses. Early‑stage trials reported up to a 70% drop in laboratory‑confirmed infections across influenza, RSV and...
Indonesia faces mounting food‑security pressures as climate stress and import dependence strain its staple‑centric agriculture. Gene‑editing technologies, touted for precise, non‑transgenic trait improvements, are being positioned to boost rice, cassava and sorghum yields. Yet stakeholder interviews reveal deep skepticism, especially...
A recent Mol Psychiatry study reveals that poly‑ADP‑ribose polymerase 1 (PARP1) activation is indispensable for long‑term synaptic potentiation (LTP) and memory formation. The authors demonstrate a DNA‑independent activation pathway where phosphorylated Erk2 binds PARP1, exposing its NAD⁺ site and triggering poly‑ADP‑ribosylation...
Suppressor tRNAs are emerging as a versatile platform to overcome premature stop codons that limit many gene‑editing and RNA‑based therapies. Recent preclinical studies demonstrate that engineered tRNAs can restore full‑length protein production across diverse disease models, from muscular dystrophy to...
China’s National Medical Products Administration approved GSK’s mepolizumab (Nucala) as an add‑on maintenance therapy for adults with eosinophilic COPD, making it the first monthly biologic for the disease in the country. The decision rests on Phase III MATINEE and METREX trials...
Researchers identified the voltage‑gated sodium channel NaV1.3 as a selective, drug‑gable target in adult lymphatic smooth muscle. Using the scorpion‑venom‑derived activator Tf2, they fully restored lymphatic vessel contractility in aged mice and partially rescued radiation‑induced deficits. NaV1.3 is absent from...
The article reviews the role of the neonatal Fc receptor (FcRn) in extending IgG half‑life and outlines how therapeutic blockade of this pathway can reduce pathogenic antibodies in autoimmune diseases. It surveys the currently approved FcRn‑targeting biologics, such as efgartigimod...
Researchers at the Chinese Academy of Sciences unveiled SPARK‑seq, a high‑throughput platform that merges CRISPR perturbations, single‑cell multi‑omics and aptamer sequencing to map aptamer‑target interactions in native cellular contexts. In a proof‑of‑concept study, the system screened over 8,000 single cells,...
Researchers at the University of Hawaiʻi at Mānoa have demonstrated how synthetic biology and CRISPR‑based metabolic engineering can boost microalgae’s production of lipids and terpenoids, key feedstocks for renewable jet fuel, bio‑based chemicals, and pharmaceuticals. The study, published in Plant...
Raj Puri, chief commercial officer of Argonaut Manufacturing, warns that U.S. tariffs will keep pressuring pharma manufacturers in 2026, extending costs and timelines for new or upgraded facilities. He highlights that large capital projects face uncertainty in a volatile geopolitical...
Meri Beckwith, Co‑CEO of Lindus Health, outlines how 2025 trends will shape pharma in 2026. AI moved from experimental to strategic, accelerating trial design, site selection and patient matching. Decentralized trial models combined with real‑world data enable nationwide recruitment and...
FUJIFILM Irvine Scientific rebranded as FUJIFILM Biosciences on Jan. 1, 2026, aligning its name with a 55‑year legacy in cell‑culture media and bioprocessing. The change underscores the unit’s shift toward biologics manufacturing and CDMO services. Recent strategic moves include a $3 billion, 10‑year...
Saharsh Davuluri of Neuland Labs outlines a digital overhaul of API manufacturing, leveraging AI tools such as Merck’s Synthia and automated parallel synthesizers to design scalable processes. He envisions a fully paperless plant where electronic batch records feed directly into...
The article presents a technical assessment of compendial tests across the European Pharmacopoeia, USP‑NF, and Japanese Pharmacopoeia to establish specification equivalence for pharmaceutical excipients. It recommends standardizing on the Ph. Eur. method for most tests, applying the tightest acceptance criteria, and...
Nearly every corn seed planted in Colorado is coated with a neonicotinoid insecticide, a practice that protects seedlings but also introduces the chemical into plants, soil and water. Environmental groups are drafting legislation that would ban such coatings unless farmers...
Researchers at Lund University used machine learning to repurpose existing drugs for high‑risk neuroblastoma. They identified a synergistic combination of a statin and a phenothiazine that markedly slowed tumor growth in mouse models. Laboratory trials showed reduced tumor cholesterol, increased...
The study shows that mice carrying the 15q duplication exhibit ~1.5‑fold elevation of GABA A‑α5 receptors in cortex, hippocampus and striatum, leading to heightened inhibitory synaptic activity and a characteristic increase in beta‑band EEG power. Chronic oral administration of the selective...
The post highlights recent advances in stem cell niche research, focusing on bone‑marrow organoid models, niche‑preserving intestinal transplants, and the discovery of tripotent Lgr5+ stem cells in the posterior tongue that generate lingual, taste, and salivary lineages. It curates related...
St. Jude Children’s Research Hospital unveiled CHANGE‑seq‑BE, a new assay that sensitively maps off‑target activity of CRISPR base editors while using only a fraction of sequencing resources. The method, published in Nature Biotechnology, demonstrated 95.4 % on‑target specificity in an FDA‑emergency case...
This systematic review examined how stressful life events during adolescence reshape epigenetic landscapes and elevate depression risk later in life. By screening 30 preclinical and clinical studies, the authors identified consistent DNA methylation and micro‑RNA changes—particularly affecting the BDNF pathway—in...
Roche has announced that Dr. Harmeier is returning to head its Roche Venture Fund, the pharma giant’s dedicated early‑stage investment arm. Harmeier previously led the fund from 2015 to 2020 before moving to a senior role within Roche’s corporate development...
Insilico Medicine saw its stock surge after debuting on the Hong Kong Stock Exchange, climbing roughly 45% on the first trading day. The secondary offering raised about $1.2 billion, pushing the company’s market capitalization past the $10 billion mark. The strong demand...
BioCentury released its "Best of BioCentury 2025" collection, curating the year’s most consequential biotech stories from its editorial team. The anthology spotlights breakthroughs in gene‑editing, AI‑driven drug discovery, and evolving regulatory frameworks. By distilling these seminal moments, BioCentury reinforces its mission...
Senator Bernie Sanders halted a Senate vote to reauthorize the rare pediatric disease priority review voucher (PRV) program, demanding unrelated multi‑billion‑dollar spending measures be adopted first. Although he expressed support for the PRV incentive, Sanders made clear his conditions would...
Ardena US managing director Ian Bilodeau says AI is reshaping pharma by linking fragmented data and speeding product decisions. He also emphasizes that attracting and developing top talent requires challenging, impact‑focused work environments. Sustainability, highlighted by Ardena’s EcoVadis certification, is...
Remco Munnik of Arcana Life Sciences says European regulators are cementing a data‑first approach, with the EMA’s electronic product database and digital submission forms becoming standard. The pharma sector is eager to embed AI for document automation and quality oversight,...
The author graded 25 2025 predictions for stem cell and regenerative medicine, finding most were accurate despite some disappointing headlines. Key highlights include reduced FDA oversight paired with notable warnings in the perinatal space, a successful Mesoblast approval, and several...
Zoliflodacin (ETX-0914) received FDA approval as an oral bacterial type II topoisomerase inhibitor for the treatment of urogenital gonorrhea. The drug emerged from rational design of earlier inhibitors and is the product of a partnership among AstraZeneca, Entasis, Innoviva and GARDP....
Charles Ross & Son introduced the DCB-5 Double Cone Tumble Blender, a five‑cubic‑foot unit designed for high‑density powder processing. The machine combines a stainless‑steel jacket, a 2 HP intensifier bar, and an integrated vacuum system to deliver repeatable homogeneity and simultaneous...
Scientists have unveiled a zero‑shot learning framework that phenotypes maize cob geometry without any model retraining. The system combines text‑guided object detection, lightweight segmentation, and calibrated trait extraction, delivering 98‑100% detection accuracy and over 0.95 correlation for trait estimates. It...
Manish Garg of Hikma Pharmaceuticals highlighted how AI, personalized medicine, and smart manufacturing reshaped pharma in 2025 and set the agenda for 2026. AI accelerated drug discovery and clinical design, while niche, high‑value therapies gained prominence. Companies are regionalizing supply...
Researchers at Scripps have unveiled vCATCH, a whole‑body imaging platform that lights up covalent drugs at single‑cell resolution in mice. By attaching a tiny chemical handle to drugs and using highly selective click‑chemistry, the method tags each bound molecule with...
ArisGlobal’s senior VP Jason Bryant argues that both human‑in‑the‑loop (HITL) and human‑on‑the‑loop (HOTL) remain essential for deploying agentic AI in pharma. He uses an air‑traffic‑control analogy, portraying AI agents as aircraft and the orchestration layer as air‑traffic management. Bryant stresses...
If restoring youthful function in old tissues sounds radical, remember that surgery without pain once did to
The biotech community mourned the loss of several iconic figures in 2025, including Nobel laureate David Baltimore and industry pioneer Rutter. Their careers spanned groundbreaking scientific discoveries, the founding of biotech firms, and the cultivation of global research ecosystems. The...
In 2025 the pharmaceutical sector saw a surge of novel therapies, notably next‑generation biologics such as bispecifics, fusion proteins, multi‑specifics, and a wave of antibody‑drug conjugates (ADCs). A breakthrough sub‑category, antibody‑oligo conjugates (AOCs), gained traction for muscular dystrophy, highlighted by...
